Moderna, Inc. (MRNA:NSD) has seen several changes to its shareholder base, with Avaii Wealth Management LLC selling 27% of its holdings in the company during the fourth quarter, according to the firm’s recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor now owns 2,287 shares of Moderna stock worth $411,000.
Other institutional investors, such as K.J. Harrison & Partners and Lindbrook Capital, have acquired shares in the company during the same period.
The company has also received a number of ratings from Wall Street analysts, with a consensus rating of “Hold” and an average target price of $166.46.
In insider news, the company’s Director, Noubar Afeyan, has sold 10,000 shares of Moderna stock in January 2022, bringing the total value of the transaction to $1,821,500. Following the sale, the Director holds 2,267,209 shares in the company, valued at $412,972,119.35.
Shannon Thyme Klinger, an insider in Moderna, sold 459 shares of the company’s stock in March 2022, with a total transaction value of $62,621.37.
Moderna stock shares are trading at $155.56 as of Monday, with a 1-year low of $115.03 and a 1-year high of $217.25. The company has a market capitalization of $60.10 billion and a PE ratio of 7.69.
Company Profile:
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
